Astellas Pharma Inc. and Iveric bio, Inc. announced that, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc. a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.
For the relief of symptoms of colds and influenza, including the relief of aches and pains, sore throat, headache, nasal congestion, lowering of temperature and chesty coughs.
This product relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. This product is indicated in pregnant and lactating women making a quit attempt.
ANI Pharmaceuticals announced that it and Sofgen has received approval from the FDA of the Abbreviated New Drug Application (ANDA)...